ArticleBMC medicine2026
Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScreening heavy smokers with low-dose computed tomography (LDCT) has been shown to reduce lung cancer (LC) mortality, however, identifying the specific high-risk population that benefits most, a critical requirement for implementing effective and cost-efficient screening, remains challenging.
methodsWe developed and validated a blood-based DNA methylation marker model (BBDMM) for all participants, including both ever and never smokers, using the LC risk-informative CpG sites from epigenome-wide association studies (EWAS). The model was developed and internally validated in 2,459 participants from ESTHER, a population-based cohort from Germany. Subsequently, BBDMM was externally validated in exactly same 233 participants drawn from the Norwegian HUNT2 and HUNT3 cohorts with long- and short-term follow-ups and cases identified up to 18 and 6.7 years before LC diagnosis, respectively.
resultsThe BBDMM predicted LC incidence with an area under the curve (AUC) of 0.84 [95% confidence interval (95% CI), 0.80-0.87] in the derivation set. In the independent external validation sets, AUCs of 0.85 (95% CI, 0.80-0.90) and 0.85 (95% CI, 0.80-0.90) were observed in HUNT2 and HUNT3, respectively.
conclusionsThe BBDMM identified future lung cancer cases with promising potential and the model discrimination was highly stable at different time points. These markers may contribute to the evolution of a blood-based test for predicting LC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.